Previous 10 | Next 10 |
Intercept Pharma (NASDAQ:ICPT) said on Wednesday the first patient had been dosed in a Phase 2 study evaluating a fixed-dose combination of its drug, obeticholic acid with bezafibrate for the treatment of patients with primary biliary cholangitis, a rare liver condition. The company...
MORRISTOWN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the first patient has been dose...
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2022 Earnings Conference Call May 6, 2022, 08:30 AM ET Company Participants Nareg Sagherian - ED, IR Jerome Durso - President and CEO Andrew Saik - CFO Linda Richardson - Chief Commercial Officer Michelle Berrey - President of Research & Developme...
Intercept Pharmaceuticals Inc. ( NASDAQ: ICPT ) shares are up 30% after announcing an agreement to sell some of its foreign subsidiaries plus rights to its international operation, including the Ocaliva commercialization license outside the US, to Advanz Pharma. Advanz is a phar...
Intercept Pharma press release (NASDAQ:ICPT): Q1 GAAP EPS of -$0.58 beats by $0.37. Revenue of $88.58M (+8.4% Y/Y) misses by $1.9M. As of March 31, 2022, cash, cash equivalents, restricted cash, and investment debt securities available for sale of approximately $406.9 million. Shares -1.99% P...
Worldwide Ocaliva ® net sales of $88.6 million, representing 8% growth over the prior year quarter Nearing completion of new REGENERATE data analyses; planning for potential pre-submission meeting with FDA in June Continue to expect topline results from Phase 3 ...
Stocks plunged on Thursday, with the Nasdaq falling 5% and recording its biggest single-day percentage decline since mid-2020. Worries about interest rates and the economy contributed to the sell-off. Online retailers were among the leaders of the decline. Earnings reports from several indust...
Intercept Pharma (NASDAQ:ICPT) is scheduled to announce Q1 earnings results on Friday, May 6th, before market open. The consensus EPS Estimate is -$0.69 (+43.4% Y/Y) and the consensus Revenue Estimate is $90.48M (+10.7% Y/Y). Over the last 1 year, ICPT has beaten EPS estimates 50% of the time...
ABR,ACMR,AEE,AES,ASIX,ATHX,AXL,BBU,BCC,BEP,BKI,BWEN,CI,CLMT,CNK,CNTY,CPLP,DISH,DKNG,EAF,ECOM,ENB,EOG,ESNT,FLR,FWONA,FYBR,GLP,GT,GTN,HYZN,OTCPK:ICAGY,ICPT,IEP,IMGN,ING,INTT,LSXMK,MITT,NRG,OCGN,OFS,OIIM,PRLB,PTR,QRTEA,ROAD,RUTH,SII,SPB,SR,SSP,TAC,TSAT,TTSH,TU,UA,UAA,VIVO,VST For Seeking Alpha's...
Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX) +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCAB) -27%. Outset Medical (OM) -10%. ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...